BCTX vs. RLMD, ETON, MIST, SCYX, BRNS, IFRX, BNTC, CMRX, IOBT, and TLSA
Should you be buying BriaCell Therapeutics stock or one of its competitors? The main competitors of BriaCell Therapeutics include Relmada Therapeutics (RLMD), Eton Pharmaceuticals (ETON), Milestone Pharmaceuticals (MIST), SCYNEXIS (SCYX), Barinthus Biotherapeutics (BRNS), InflaRx (IFRX), Benitec Biopharma (BNTC), Chimerix (CMRX), IO Biotech (IOBT), and Tiziana Life Sciences (TLSA). These companies are all part of the "pharmaceutical preparations" industry.
Relmada Therapeutics (NASDAQ:RLMD) and BriaCell Therapeutics (NASDAQ:BCTX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability, media sentiment and community ranking.
Relmada Therapeutics received 11 more outperform votes than BriaCell Therapeutics when rated by MarketBeat users. However, 100.00% of users gave BriaCell Therapeutics an outperform vote while only 41.03% of users gave Relmada Therapeutics an outperform vote.
Relmada Therapeutics has a beta of 0.27, meaning that its share price is 73% less volatile than the S&P 500. Comparatively, BriaCell Therapeutics has a beta of 1.14, meaning that its share price is 14% more volatile than the S&P 500.
45.2% of Relmada Therapeutics shares are owned by institutional investors. Comparatively, 15.4% of BriaCell Therapeutics shares are owned by institutional investors. 18.0% of Relmada Therapeutics shares are owned by insiders. Comparatively, 21.8% of BriaCell Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
BriaCell Therapeutics is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks.
Relmada Therapeutics currently has a consensus price target of $25.00, suggesting a potential upside of 733.33%. BriaCell Therapeutics has a consensus price target of $18.00, suggesting a potential upside of 965.09%. Given Relmada Therapeutics' higher possible upside, analysts clearly believe BriaCell Therapeutics is more favorable than Relmada Therapeutics.
Relmada Therapeutics' return on equity of 0.00% beat BriaCell Therapeutics' return on equity.
In the previous week, Relmada Therapeutics had 1 more articles in the media than BriaCell Therapeutics. MarketBeat recorded 3 mentions for Relmada Therapeutics and 2 mentions for BriaCell Therapeutics. Relmada Therapeutics' average media sentiment score of 0.94 beat BriaCell Therapeutics' score of 0.80 indicating that BriaCell Therapeutics is being referred to more favorably in the news media.
Summary
BriaCell Therapeutics beats Relmada Therapeutics on 10 of the 14 factors compared between the two stocks.
Get BriaCell Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BCTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BriaCell Therapeutics Competitors List
Related Companies and Tools
